Chimeric Hsp90β-selective inhibitors keep selectivity while tuning PK
- Pan-Hsp90 inhibitors stalled clinically because of their broad inhibition, so Hsp90β-selective indazolone compounds have been pursued, though earlier ones needed long optimization to become drug-like.
- This work modifies the northern indazolone fragment and the southwestern appendage at the same time, testing whether the best traits of each region can be combined.
- The resulting chimeric inhibitors retain Hsp90β affinity and selectivity while shifting key pharmacokinetic parameters.
💡 Points
Merging two independently optimized vectors is a sensible, low-risk move, and selectivity surviving the merge suggests the β-specific pocket tolerates more change than I feared. What would decide it for me is tissue exposure and tolerability, since that is where pan-inhibitors failed.